Lamberti, G.; Prinzi, N.; Bongiovanni, A.; Torniai, M.; Andrini, E.; Biase, D.d.; Malvi, D.; Mosca, M.; Berardi, R.; Ibrahim, T.;
et al. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics 2023, 13, 1595.
https://doi.org/10.3390/diagnostics13091595
AMA Style
Lamberti G, Prinzi N, Bongiovanni A, Torniai M, Andrini E, Biase Dd, Malvi D, Mosca M, Berardi R, Ibrahim T,
et al. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics. 2023; 13(9):1595.
https://doi.org/10.3390/diagnostics13091595
Chicago/Turabian Style
Lamberti, Giuseppe, Natalie Prinzi, Alberto Bongiovanni, Mariangela Torniai, Elisa Andrini, Dario de Biase, Deborah Malvi, Mirta Mosca, Rossana Berardi, Toni Ibrahim,
and et al. 2023. "Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET)" Diagnostics 13, no. 9: 1595.
https://doi.org/10.3390/diagnostics13091595
APA Style
Lamberti, G., Prinzi, N., Bongiovanni, A., Torniai, M., Andrini, E., Biase, D. d., Malvi, D., Mosca, M., Berardi, R., Ibrahim, T., Pusceddu, S., & Campana, D.
(2023). Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET). Diagnostics, 13(9), 1595.
https://doi.org/10.3390/diagnostics13091595